Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is the nation’s first pay-for-performance insurance for oncology and covers 34 Chinese cities, according to state-run newspaper China Daily.
Pfizer developed the Bo’ai Xin’an – Patient Benefit Management Program in collaboration with insurance company Shanghai Branch of PICC Health Insurance Co. Ltd. (Beijing, China) and medical payment services company Shanghai MediTrust Health Co. Ltd. (Shanghai, China).
It will reimburse enrolled patients up to 33.5% of their Ibrance treatment cost if they experience disease progression or metastasis within the first 126 days of starting treatment with Ibrance in combination with an aromatase inhibitor, according to a MediTrust spokesperson. Only patients who have had no previous first-line endocrine therapy treatment are eligible, and they must enroll in the program within 28 days of beginning Ibrance treatment. Enrollment in the program is capped at 500 patients.
Ibrance, a dual inhibitor of CDK4 and CDK6, gained Chinese approval in August to treat breast cancer in combination with an aromatase inhibitor.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.